You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
Biological Activity for FHT 2344
FHT 2344 is a potent allosteric and ATP-competitive inhibitor of SMARCA2/SMARCA4 ATPases (also known as BRM/BRG1) of the BAF complex (IC50 values are 13.8 and 26.1 nM at SMARCA2 and SMARCA4, respectively). FHT 2344 inhibits SMARCA2 transcriptional activity in a BRG1-mutant cell line and SMARCA4 transcription in a BRM-mutant cell line (IC50 values are 29.8 and 30.2 nM, respectively). Dose-dependently reduces tumor growth in a uveal melanoma xenograft model and suppresses SOX10 transcription.
Sold under license from Foghorn Therapeutics
Technical Data for FHT 2344
|Storage||Store at -20°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solubility Data for FHT 2344
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions for FHT 2344
The following data is based on the product molecular weight 528.6. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|0.5 mM||3.78 mL||18.92 mL||37.84 mL|
|2.5 mM||0.76 mL||3.78 mL||7.57 mL|
|5 mM||0.38 mL||1.89 mL||3.78 mL|
|25 mM||0.08 mL||0.38 mL||0.76 mL|
References for FHT 2344
References are publications that support the biological activity of the product.
Centore et al (2021) Discovery of novel BAF inhibitors for the treatment of transcription factor-driven cancers. Cancer Res. 81 1224
If you know of a relevant reference for FHT 2344, please let us know.
View Related Products by Product Action
Keywords: FHT 2344, FHT 2344 supplier, FHT2344, SMARCA, SMARCA2, SMARCA4, potent, inhibitor, inhibitors, BRM, BRG1, BAF, complex, transcription, tumour, tumor, uveal, melanoma, xenograft, SOX10, Bromodomains, Other, ATPases, 7645, Tocris Bioscience
Citations for FHT 2344
Citations are publications that use Tocris products.
Currently there are no citations for FHT 2344. Do you know of a great paper that uses FHT 2344 from Tocris? Please let us know.
Reviews for FHT 2344
There are currently no reviews for this product. Be the first to review FHT 2344 and earn rewards!
Have you used FHT 2344?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Epigenetics Scientific Review
Written by Susanne Müller-Knapp and Peter J. Brown, this review gives an overview of the development of chemical probes for epigenetic targets, as well as the impact of these tool compounds being made available to the scientific community. In addition, their biological effects are also discussed. Epigenetic compounds available from Tocris are listed.
Epigenetics in Cancer Poster
This poster summarizes the main epigenetic targets in cancer. The dysregulation of epigenetic modifications has been shown to result in oncogenesis and cancer progression. Unlike genetic mutations, epigenetic alterations are considered to be reversible and thus make promising therapeutic targets.
Rheumatoid Arthritis Poster
Rheumatoid arthritis (RA) is a chronic destructive inflammatory autoimmune disease that results from a breakdown in immune tolerance, for reasons that are as yet unknown. This poster summarizes the pathology of RA and the inflammatory processes involved, as well as describing some of the epigenetic modifications associated with the disease and the potential for targeting these changes in the discovery of new treatments.